

## Publications for Nick Lintzeris

### 2019

Jacobs, N., Montebello, M., Monds, L., Lintzeris, N. (2019). Survey of Australian psychiatrists' and psychiatry trainees' knowledge about and attitudes towards medicinal cannabinoids. *Australasian Psychiatry*, 27(1), 80-85. <a href="http://dx.doi.org/10.1177/1039856218803675">[More Information]</a>

### 2018

Lintzeris, N., Demirkol, A. (2018). A woman with pain and codeine withdrawal: Treatment to support opioid cessation. *Medicine Today*, March 2018(3 Suppl), 31-32.

Dwyer, R., Olsen, A., Fowle, C., Gough, C., Van Beek, I., Jauncey, M., Lintzeris, N., Oh, G., Dicka, J., Fry, C., et al (2018). An overview of take-home naloxone programs in Australia. *Drug and Alcohol Review*, 37(4), 440-449. <a href="http://dx.doi.org/10.1111/dar.12812">[More Information]</a>

Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. *Scientific Reports*, 8(1), 1-1. <a href="http://dx.doi.org/10.1038/s41598-018-30164-8">[More Information]</a>

Ridley, N., Batchelor, J., Draper, B., Demirkol, A., Lintzeris, N., Withall, A. (2018). Cognitive screening in substance users: Diagnostic accuracies of the Mini-Mental State Examination, Addenbrooke's Cognitive Examination<sup>1</sup>/<sub>2</sub> Revised, and Montreal Cognitive Assessment. *Journal of Clinical and Experimental Neuropsychology*, 40(2), 107-122. <a href="http://dx.doi.org/10.1080/13803395.2017.1316970">[More Information]</a>

Lovell, M., Bruno, R., Johnston, J., Matthews, A., McGregor, I., Allsop, D., Lintzeris, N. (2018). Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. *Addictive Behaviors*, 79, 178-188. <a href="http://dx.doi.org/10.1016/j.addbeh.2017.12.009">[More Information]</a>

Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. *Scientific Reports*, 8(1), 28127. <a href="http://dx.doi.org/10.1038/s41598-018-28127-0">[More Information]</a>

Bleeker, A., Crowther, M., Darke, S., Lintzeris, N., McGregor, I. (2018). David J. Allsop (7.12.1974-2013.8.2018). *Drug and Alcohol Review*, 37(7), 922-923. <a href="http://dx.doi.org/10.1111/dar.12865">[More Information]</a>

Dietze, P., Draper, B., Olsen, A., Chronister, K., Van Beek, I., Lintzeris, N., Dwyer, R., Nelson, M., Lenton, S. (2018). Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs. *Drug and Alcohol Review*, 37(4), 472-479. <a href="http://dx.doi.org/10.1111/dar.12680">[More Information]</a>

Campbell, G., Hall, W., Peacock, A., Lintzeris, N., Bruno, R.,

Larance, B., Nielsen, S., Cohen, M., Chan, G., Mattick, R., Blyth, F., et al (2018). Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. *The Lancet Public Health*, 3(7), e341-e350. <a href="http://dx.doi.org/10.1016/S2468-2667(18)30110-5">[More Information]</a>

Chronister, K., Lintzeris, N., Jackson, A., Ivan, M., Dietze, P., Lenton, S., Kearley, J., Van Beek, I. (2018). Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program. *Drug and Alcohol Review*, 37, 464-471. <a href="http://dx.doi.org/10.1111/dar.12400">[More Information]</a>

Nielsen, S., Peacock, A., Lintzeris, N., Bruno, R., Larance, B., Degenhardt, L. (2018). Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. *Pain Medicine*, 19(3), 533-540. <a href="http://dx.doi.org/10.1093/pm/pnx021">[More Information]</a>

Ezard, N., Dunlop, A., Hall, M., Ali, R., McKetin, R., Bruno, R., Phung, N., Carr, A., White, J., Clifford, M., Lintzeris, N., et al (2018). LiMA: A study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. *BMJ Open*, 8(7). <a href="http://dx.doi.org/10.1136/bmjopen-2017-020723">[More Information]</a>

Lintzeris, N., Driels, J., Elias, N., Arnold, J., McGregor, I., Allsop, D. (2018). Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16). *Medical Journal of Australia*, 209(5), 211-216. <a href="http://dx.doi.org/10.5694/mja17.01247">[More Information]</a>

Mersiades, A., Tognela, A., Haber, P., Stockler, M., Lintzeris, N., Simes, R., McGregor, I., Olver, I., Allsop, D., Gedye, C., Kirby, A., Morton, R., Doo, N., Walsh, A., Grimison, P., et al (2018). Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). *BMJ Open*, 8(9), 1-8. <a href="http://dx.doi.org/10.1136/bmjopen-2017-020745">[More Information]</a>

Bhardwaj, A., Allsop, D., Copeland, J., McGregor, I., Dunlop, A., Shanahan, M., Bruno, R., Phung, N., Montebello, M., Sadler, C., Gugusheff, J., Lintzeris, N., et al (2018). Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. *BMC Psychiatry*, 18(1), 140. <a href="http://dx.doi.org/10.1186/s12888-018-1682-2">[More Information]</a>

Bell, J., Belackova, V., Lintzeris, N. (2018). Supervised Injectable Opioid Treatment for the Management of Opioid Dependence. *Drugs*, 78(13), 1339-1352. <a href="http://dx.doi.org/10.1007/s40265-018-0962-y">[More Information]</a>

Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., Simes, R., Stockler, M., Morton, R. (2018). Systematic Review of the Costs and Benefits of Prescribed

Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. *PharmacoEconomics*, 36(1), 67-78. <a href="http://dx.doi.org/10.1007/s40273-017-0565-6">[More Information]</a>

Larance, B., Dobbins, T., Peacock, A., Ali, R., Bruno, R., Lintzeris, N., Farrell, M., Degenhardt, L. (2018). The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. *The Lancet Psychiatry*, 5(2), 155-166. <a href="http://dx.doi.org/10.1016/S2215-0366(18)30003-8">[More Information]</a>

Lintzeris, N., Monds, L., Rivas, C., Leung, S., Dunlop, A., Newcombe, D., Walters, C., Galea, S., White, N., Montebello, M., et al (2018). Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines. *Journal of Addiction Medicine*, 12(3), 234-240. <a href="http://dx.doi.org/10.1097/ADM.0000000000000396">[More Information]</a>

## 2017

Suraev, A., Todd, L., Bowen, M., Allsop, D., McGregor, I., Ireland, C., Lintzeris, N. (2017). An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. *Epilepsy and Behavior*, 70, 334-340. <a href="http://dx.doi.org/10.1016/j.yebeh.2017.02.005">[More Information]</a>

Monds, L., Ridley, N., Rivas, C., Withall, A., Draper, B., Lintzeris, N. (2017). Cognition and adaptive functioning in older people attending drug and alcohol services. *International Psychogeriatrics*, 29(5), 815-823. <a href="http://dx.doi.org/10.1017/S1041610216002428">[More Information]</a>

Haber, P., Elsayed, M., Espinoza, D., Lintzeris, N., Veillard, A., Hallinan, R. (2017). Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. *Drug and Alcohol Dependence*, 181, 132-139. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2017.09.024">[More Information]</a>

Nielsen, S., Gisev, N., Bruno, R., Hall, W., Cohen, M., Larance, B., Campbell, G., Shanahan, M., Blyth, F., Lintzeris, N., Pearson, S., et al (2017). Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. *Pharmacoepidemiology and Drug Safety*, 26(5), 587-591. <a href="http://dx.doi.org/10.1002/pds.4168">[More Information]</a>

Dunlop, A., Brown, A., Oldmeadow, C., Harris, A., Gill, A., Sadler, C., Ribbons, K., Attia, J., Barker, D., et al, Lintzeris, N. (2017). Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial. *Drug and Alcohol Dependence*, 174, 181-191. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2017.01.016">[More Information]</a>

Nielsen, S., Bruno, R., Degenhardt, L., Demirkol, A., Lintzeris, N. (2017). Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. *Drug and Alcohol Review*, 36(3), 311-316. <a href="http://dx.doi.org/10.1111/dar.12418">[More Information]</a>

Nielsen, S., Larance, B., Lintzeris, N. (2017). Opioid agonist treatment for patients with dependence on prescription opioids. *JAMA - Journal of the American Medical Association*, 317(9), 967-968. <a href="http://dx.doi.org/10.1001/jama.2017.0001">[More Information]</a>

href="http://dx.doi.org/10.1001/jama.2017.0001">[More Information]</a>

Nielsen, S., Sabioni, P., Trigo, J., Ware, M., Betz-Stablein, B., Murnion, B., Lintzeris, N., Khor, K., Farrell, M., Smith, A., et al (2017). Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis. *Neuropsychopharmacology*, 42(9), 1752-1765. <a href="http://dx.doi.org/10.1038/npp.2017.51">[More Information]</a>

Allsop, D., Rooney, K., Arnold, J., Bhardwaj, A., Brunu, R., Bartlett, D., Montebello, M., Arkell, T., Richards, E., Gugusheff, J., Rooke, S., Kerley, W., Murnion, B., Haber, P., McGregor, I., Lintzeris, N. (2017). Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. *Mental Health and Physical Activity*, 13, 57-67. <a href="http://dx.doi.org/10.1016/j.mhpa.2017.06.002">[More Information]</a>

Kevin, R., Allsop, D., Lintzeris, N., Dunlop, A., Booth, J., McGregor, I. (2017). Urinary cannabinoid levels during nabiximols (Sativex)-medicated inpatient cannabis withdrawal. *Forensic Toxicology*, 35(1), 33-44. <a href="http://dx.doi.org/10.1007/s11419-016-0330-0">[More Information]</a>

## 2016

Deacon, R., Nielsen, E., Leung, S., Rivas, G., Cubitt, T., Monds, L., Ezard, N., Larance, B., Lintzeris, N. (2016). Alprazolam use and related harm among opioid substitution treatment clients - 12 months follow up after regulatory rescheduling. *International Journal of Drug Policy*, 36, 104-111. <a href="http://dx.doi.org/10.1016/j.drugpo.2016.06.006">[More Information]</a>

Luckett, T., Phillips, J., Lintzeris, N., Allsop, D., Lee, J., Solowij, N., Martin, J., Lam, L., Aggarwal, R., McCaffrey, N., Lovell, M., McGregor, I., et al (2016). Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: A survey of preferences, attitudes and beliefs among patients willing to consider participation. *Internal Medicine Journal*, 46(11), 1269-1275. <a href="http://dx.doi.org/10.1111/imj.13224">[More Information]</a>

Campbell, G., Bruno, R., Lintzeris, N., Cohen, M., Nielsen, S., Hall, W., Larance, B., Mattick, R., Blyth, F., Farrell, M., et al (2016). Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain: Do different measures identify the same patients? *Pain*, 157(7), 1489-1498. <a href="http://dx.doi.org/10.1097/j.pain.0000000000000548">[More Information]</a>

Larance, B., Bruno, R., Lintzeris, N., Degenhardt, L., Black, E., Brown, A., Nielsen, S., Dunlop, A., Holland, R., Cohen, M., et al (2016). Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. *Drug and Alcohol Dependence*, 159, 42-52. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2015.11.026">[More Information]</a>

Larance, B., Mattick, R., Ali, R., Lintzeris, N., Jenkinson, R., White, N., Kihass, I., Cassidy, R., Degenhardt, L. (2016). Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. *Drug and Alcohol Review*, 35(1), 83-91. <a href="http://dx.doi.org/10.1111/dar.12344">[More Information]</a>

Information]

Arnold, J., Allsop, D., Lintzeris, N., McGregor, I. (2016). *Evidence Check: Pharmacological actions and associated therapeutic levels of phytocannabinoids*, (pp. 1 - 81). Sydney, Australia: The Sax Institute.

Larance, B., Campbell, G., Peacock, A., Nielsen, S., Bruno, R., Hall, W., Lintzeris, N., Cohen, M., Degenhardt, L. (2016). Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. *Drug and Alcohol Dependence*, 162, 79-87. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2016.02.048">[More Information]

Kraus, M., Lintzeris, N., Maier, C., Savage, S. (2016). Recommendations for the Prevention, Detection, Treatment and Management of Prescription Opioid Analgesic Dependence: Outcomes From the Opioid Analgesic Dependence Education Nexus (OPEN) Meeting. *International Journal of Mental Health and Addiction*, 14(3), 313-321. <a href="http://dx.doi.org/10.1007/s11469-015-9590-x">[More Information]

Peacock, A., Bruno, R., Larance, B., Lintzeris, N., Nielsen, S., Ali, R., Dobbins, T., Degenhardt, L. (2016). Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. *Drug and Alcohol Dependence*, 166, 125-133. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2016.07.003">[More Information]

Lintzeris, N., Moodley, R., Campbell, G., Larance, B., Bruno, R., Nielsen, E., Degenhardt, L. (2016). Sleep quality among people living with chronic noncancer pain: Findings from the pain and opioids in treatment (POINT) cohort. *Clinical Journal of Pain*, 32(5), 380-387. <a href="http://dx.doi.org/10.1097/AJP.0000000000000282">[More Information]

Ezard, N., Dunlop, A., Clifford, B., Bruno, R., Carr, A., Bissaker, A., Lintzeris, N. (2016). Study protocol: A dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. *BMC Psychiatry*, 16(1), 1-8. <a href="http://dx.doi.org/10.1186/s12888-016-1141-x">[More Information]

Lintzeris, N., Rivas, C., Monds, L., Leung, S., Withall, A., Draper, B. (2016). Substance use, health status and service utilisation of older clients attending specialist drug and alcohol services. *Drug and Alcohol Review*, 35(2), 223-231. <a href="http://dx.doi.org/10.1111/dar.12266">[More Information]

Lintzeris, N., Monds, L., Rivas, G., Leung, S., Withall, A., Draper, B. (2016). The Australian Treatment Outcomes Profile instrument as a clinical tool for older alcohol and other drug clients: A validation study. *Drug and Alcohol Review*, 35(6), 673-677. <a href="http://dx.doi.org/10.1111/dar.12393">[More Information]

Nielsen, S., Bruno, R., Murnion, B., Dunlop, A., Degenhardt, L., Demirkol, A., Muhleisen, P., Lintzeris, N. (2016). Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. *Drug and Alcohol Review*, 35(1), 70-75. <a href="http://dx.doi.org/10.1111/dar.12315">[More Information]

## 2015

Peacock, A., Degenhardt, L., Larance, B., Cama, E., Lintzeris, N., Ali, R., Bruno, R. (2015). A typology of people who tamper with pharmaceutical opioids: responses to introduction of a

tamper-resistant formulation of controlled-release oxycodone. *Pharmacoepidemiology and Drug Safety*, 24(12), 1321-1333. <a href="http://dx.doi.org/10.1002/pds.3883">[More Information]

Degenhardt, L., Bruno, R., Lintzeris, N., Hall, W., Nielsen, S., Larance, B., Cohen, M., Campbell, G. (2015). Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): A cohort study. *The Lancet Psychiatry*, 2(4), 314-322. <a href="http://dx.doi.org/10.1016/S2215-0366(15)00005-X">[More Information]

Nielsen, S., Lintzeris, N., Bruno, R., Campbell, G., Larance, B., Hall, W., Hoban, B., Cohen, M., Degenhardt, L. (2015). Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. *Pain Medicine*, 16(2), 356-366. <a href="http://dx.doi.org/10.1111/pme.12594">[More Information]

Allsop, D., Lintzeris, N., Copeland, J., Dunlop, A., McGregor, I. (2015). Cannabinoid Replacement Therapy (CRT): Nabiximols (Sativex) as a Novel Treatment for Cannabis Withdrawal. *Clinical Pharmacology & Therapeutics*, 97(6), 571-574. <a href="http://dx.doi.org/10.1002/cpt.109">[More Information]

Nielsen, S., Roxburgh, A., Bruno, R., Lintzeris, N., Jefferson, A., Degenhardt, L. (2015). Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011. *Drug and Alcohol Dependence*, 149, 212-219. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2015.02.004">[More Information]

Nielsen, S., Murnion, B., Dunlop, A., Degenhardt, L., Demirkol, A., Muhleisen, P., Lintzeris, N. (2015). Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series. *Drug and Alcohol Review*, 34(3), 304-311. <a href="http://dx.doi.org/10.1111/dar.12224">[More Information]

Metrebian, N., Groshkova, T., Hellier, J., Charles, V., Martin, A., Forzisi, L., Lintzeris, N., Zador, D., Williams, H., Carnwath, T., et al (2015). Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: Secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT). *Addiction*, 110(3), 479-490. <a href="http://dx.doi.org/10.1111/add.12748">[More Information]

Degenhardt, L., Larance, B., Bruno, R., Lintzeris, N., Ali, R., Farrell, M. (2015). Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. *Addiction*, 110(2), 226-237. <a href="http://dx.doi.org/10.1111/add.12746">[More Information]

Degenhardt, L., Lintzeris, N., Campbell, G., Bruno, R., Cohen, M., Farrell, M., Hall, W. (2015). Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. *Drug and Alcohol Dependence*, 147, 144-150. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2014.11.031">[More Information]

Strang, J., Groshkova, T., Uchtenhagen, A., van den Brink, W., Haasen, C., Schechter, M., Lintzeris, N., Bell, J., Pirrona, A., Oviedo-Joekes, E., et al (2015). Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. *British*

*Journal of Psychiatry*, 207(1), 5-14. <a href="http://dx.doi.org/10.1192/bjp.bp.114.149195">[More Information]</a>

White, N., Flaherty, I., Higgs, P., Larance, B., Nielsen, S., Degenhardt, L., Ali, R., Lintzeris, N. (2015). Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. *Drug and Alcohol Review*, 34(6), 623-629. <a href="http://dx.doi.org/10.1111/dar.12308">[More Information]</a>

Peacock, A., Bruno, R., Cama, E., Kihias, I., Larance, B., Lintzeris, N., Hordern, A., White, N., Ali, R., Degenhardt, L. (2015). Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. *Drug and Alcohol Review*, 34(6), 611-622. <a href="http://dx.doi.org/10.1111/dar.12279">[More Information]</a>

Lintzeris, N. (2015). Opioids. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), *Addiction Medicine: Principles and Practice*, (pp. 316-329). Melbourne: IP Communications.

Campbell, G., Nielsen, S., Larance, B., Bruno, R., Mattick, R., Hall, W., Lintzeris, N., Cohen, M., Smith, K., Degenhardt, L. (2015). Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. *Pain Medicine*, 16(9), 1745-1758. <a href="http://dx.doi.org/10.1111/pme.12773">[More Information]</a>

Wang, D., Lintzeris, N., Leung, S., Haber, P., Yee, B., Grunstein, R. (2015). Reversal of central sleep apnoea with change from methadone to buprenorphine-naloxone: a case report. *European Respiratory Journal*, 46(4), 1202-1205. <a href="http://dx.doi.org/10.1183/13993003.00577-2014">[More Information]</a>

Draper, B., Ridley, N., Johnco, C., Withall, A., Welke, S., Freeman, M., Contini, E., Lintzeris, N. (2015). Screening for alcohol and substance use for older people in geriatric hospital and community health settings. *International Psychogeriatrics*, 27(1), 157-166. <a href="http://dx.doi.org/10.1017/S1041610214002014">[More Information]</a>

Larance, B., Lintzeris, N., Bruno, R., Peacock, A., Cama, E., Ali, R., Kihias, I., Hordern, A., White, N., Degenhardt, L. (2015). The characteristics of a cohort who tamper with prescribed and diverted opioid medications. *Journal of Substance Abuse Treatment*, 58, 51-61. <a href="http://dx.doi.org/10.1016/j.jsat.2015.06.001">[More Information]</a>

Allsop, D., Bartlett, D., Johnston, J., Helliwell, D., Winstock, A., McGregor, I., Lintzeris, N. (2015). The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. *The Journal of Clinical Sleep Medicine*, 11(10), 1153-1162. <a href="http://dx.doi.org/10.5664/jcsm.5090">[More Information]</a>

Degenhardt, L., Bruno, R., Ali, R., Lintzeris, N., Farrell, M., Larance, B. (2015). The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. *Drug and Alcohol Dependence*, 151, 56-67. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2015.02.038">[More Information]</a>

Larance, B., Dietze, P., Ali, R., Lintzeris, N., White, N., Jenkinson, R., Degenhardt, L. (2015). The introduction of

buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. *Drug and Alcohol Review*, 34(6), 603-610. <a href="http://dx.doi.org/10.1111/dar.12277">[More Information]</a>

Campbell, G., Nielsen, S., Bruno, R., Lintzeris, N., Cohen, M., Hall, W., Larance, B., Mattick, R., Degenhardt, L. (2015). The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. *Pain*, 156(2), 231-242. <a href="http://dx.doi.org/10.1097/01.j.pain.0000460303.63948.8e">[More Information]</a>

Hoban, B., Larance, B., Gisev, N., Nielsen, S., Cohen, M., Bruno, R., Shand, F., Lintzeris, N., Hall, W., Farrell, M., et al (2015). The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. *International Journal of Clinical Practice*, 69(11), 1366-1376. <a href="http://dx.doi.org/10.1111/ijcp.12716">[More Information]</a>

Lintzeris, N. (2015). Treatment of patients with opioid dependence. *Medicine Today*, 16(6), 10-15.

## 2014

Larance, B., Carragher, N., Mattick, R., Lintzeris, N., Ali, R., Degenhardt, L. (2014). A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses? *Drug and Alcohol Dependence*, 142, 46-55. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2014.05.018">[More Information]</a>

Lofwall, M., Martin, J., Tierney, M., Fatseas, M., Auriacombe, M., Lintzeris, N. (2014). Buprenorphine diversion and misuse in outpatient practice. *Journal of Addiction Medicine*, 8(5), 327-332. <a href="http://dx.doi.org/10.1097/ADM.0000000000000029">[More Information]</a>

Campbell, G., Mattick, R., Bruno, R., Larance, B., Nielsen, S., Cohen, M., Lintzeris, N., Shand, F., Hall, W., Hoban, B., et al (2014). Cohort protocol paper: the Pain and Opioids IN Treatment (POINT) study. *BMC Pharmacology & Toxicology*, 15(1), 1-9. <a href="http://dx.doi.org/10.1186/2050-6511-15-17">[More Information]</a>

Belcher, J., Nielsen, S., Campbell, G., Bruno, R., Hoban, B., Larance, B., Lintzeris, N., Degenhardt, L. (2014). Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. *Drug and Alcohol Review*, 33(1), 27-32. <a href="http://dx.doi.org/10.1111/dar.12084">[More Information]</a>

Johnston, J., Lintzeris, N., Allsop, D., Suraev, A., Booth, J., Carson, D., Helliwell, D., Winstock, A., McGregor, I. (2014). Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. *Psychopharmacology*, 231(24), 4623-4636. <a href="http://dx.doi.org/10.1007/s00213-014-3611-5">[More Information]</a>

Allsop, D., Copeland, J., Lintzeris, N., Dunlop, A., Montebello, M., Sadler, C., Rivas, G., Holland, R., Muhleisen, P., Norberg, M., Booth, J., McGregor, I. (2014). Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial. *JAMA Psychiatry*, 71(3), 281-291. <a href="http://dx.doi.org/10.1001/jamapsychiatry.2013.3947">[More Information]</a>

Larance, B., Lintzeris, N., Ali, R., Dietze, P., Mattick, R., Jenkinson, R., White, N., Degenhardt, L. (2014). The diversion and injection of a buprenorphine-naloxone soluble film formulation. *Drug and Alcohol Dependence*, 136(1), 21-27. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2013.12.005">[More Information]</a>

## 2013

Lintzeris, N., Leung, S., Dunlop, A., Larance, B., White, N., Rivas, G., Holland, R., Degenhardt, L., Muhleisen, P., Hurley, M., et al (2013). A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. *Drug and Alcohol Dependence*, 131(1-2), 119-126. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2012.12.009">[More Information]</a>

Holliday, S., Magin, P., Dunbabin, J., Oldmeadow, C., Henry, J., Lintzeris, N., Attia, J., Goode, S., Dunlop, A. (2013). An Evaluation of the Prescription of Opioids for Chronic Nonmalignant Pain by Australian General Practitioners. *Pain Medicine*, 14(1), 62-74. <a href="http://dx.doi.org/10.1111/j.1526-4637.2012.01527.x">[More Information]</a>

Holliday, S., Magin, P., Oldmeadow, C., Attia, J., Dunbabin, J., Henry, J., Lintzeris, N., Goode, S., Dunlop, A. (2013). An examination of the influences on New South Wales general practitioners regarding the provision of opioid substitution therapy. *Drug and Alcohol Review*, 32(5), 495-503. <a href="http://dx.doi.org/10.1111/dar.12046">[More Information]</a>

Nielsen, S., Larance, B., Lintzeris, N., Black, E., Bruno, R., Murnion, B., Dunlop, A., Degenhardt, L. (2013). Correlates of pain in an in-treatment sample of opioid-dependent people. *Drug and Alcohol Review*, 32(5), 489-494. <a href="http://dx.doi.org/10.1111/dar.12041">[More Information]</a>

Wong, A., Montebello, M., Norberg, M., Rooney, K., Lintzeris, N., Bruno, R., Booth, J., Arnold, J., McGregor, I. (2013). Exercise increases plasma THC concentrations in regular cannabis users. *Drug and Alcohol Dependence*, 133(2), 763-767. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2013.07.031">[More Information]</a>

Nielsen, S., Bruno, R., Degenhardt, L., Stoove, M., Fischer, J., Carruthers, S., Lintzeris, N. (2013). The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. *Medical Journal of Australia*, 199(10), 696-699. <a href="http://dx.doi.org/10.5694/mja12.11331">[More Information]</a>

Groshkova, T., Metrebian, N., Hallam, C., Charles, V., Martin, A., Forzisi, L., Lintzeris, N., Strang, J. (2013). Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics. *Drug and Alcohol Review*, 32(6), 566-573. <a href="http://dx.doi.org/10.1111/dar.12062">[More Information]</a>

## 2012

Day, C., Demirkol, A., Tynan, M., Curry, K., Hines, S., Lintzeris, N., Haber, P. (2012). Individual versus team-based case-management for clients of opioid treatment services: An initial evaluation of what clients prefer. *Drug and Alcohol Review*, 31(4), 499-506. <a href="http://dx.doi.org/10.1111/j.1465-3362.2011.00347.x">[More Information]</a>

Black, K., Haber, P., Lintzeris, N. (2012). Offering incentives to drug-using women to take up contraception: The ethical and clinical issues. *Addiction*, 107(7), 1361-1362. <a href="http://dx.doi.org/10.1111/j.1360-0443.2012.03873.x">[More Information]</a>

Black, K., Stephens, C., Haber, P., Lintzeris, N. (2012). Unplanned pregnancy and contraceptive use in women attending drug treatment services. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 52(2), 146-150. <a href="http://dx.doi.org/10.1111/j.1479-828X.2012.01413.x">[More Information]</a>

## 2011

Winstock, A., Lintzeris, N., Lea, T. (2011). 'Should I stay or should I go?' Coming off methadone and buprenorphine treatment. *International Journal of Drug Policy*, 22(1), 77-81. <a href="http://dx.doi.org/10.1016/j.drugpo.2010.08.001">[More Information]</a>

Larance, B., Degenhardt, L., Lintzeris, N., Winstock, A., Mattick, R. (2011). Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. *Drug and Alcohol Review*, 30(3), 236-245. <a href="http://dx.doi.org/10.1111/j.1465-3362.2010.00283.x">[More Information]</a>

Longman, C., Lintzeris, N., Temple-Smith, M., Gilchrist, G. (2011). Methadone and buprenorphine prescribing patterns of Victorian general practitioners: Their first 5 years after authorisation. *Drug and Alcohol Review*, 30(4), 355-359. <a href="http://dx.doi.org/10.1111/j.1465-3362.2010.00212.x">[More Information]</a>

Mayet, S., Gossop, M., Lintzeris, N., Markides, V., Strang, J. (2011). Methadone maintenance, QTc and torsade de pointes: Who needs an electrocardiogram and what is the prevalence of QTc prolongation? *Drug and Alcohol Review*, 30(4), 388-396. <a href="http://dx.doi.org/10.1111/j.1465-3362.2010.00237.x">[More Information]</a>

Nielsen, S., Bruno, R., Lintzeris, N., Fischer, J., Carruthers, S., Stoove, M. (2011). Pharmaceutical opioid analgesic and heroin dependence: How do treatment-seeking clients differ in Australia? *Drug and Alcohol Review*, 30(3), 291-299. <a href="http://dx.doi.org/10.1111/j.1465-3362.2011.00302.x">[More Information]</a>

Larance, B., Degenhardt, L., Lintzeris, N., Bell, J., Winstock, A., Dietze, P., Mattick, R., Ali, R., Horyniak, D. (2011). Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. *Drug and Alcohol Dependence*, 118(2011), 265-273. <a href="http://dx.doi.org/10.1016/j.drugalcdep.2011.04.002">[More Information]</a>

Douglas, H., Boyle, M., Lintzeris, N. (2011). The health impacts of khat: a qualitative study among Somali-Australians. *Medical Journal of Australia*, 195(11), 666-669. <a href="http://dx.doi.org/10.5694/mja11.10166">[More Information]</a>

## 2010

Lintzeris, N., Nielsen, S. (2010). Benzodiazepines, methadone and buprenorphine: interactions and clinical management. *American Journal on Addictions*, 19(1), 59-72. <a href="http://dx.doi.org/10.1111/j.1521-0391.2009.00007.x">[More Information]</a>

Lintzeris, N. (2010). Commentary on Blanken et al. (2010): long-term heroin-assisted treatment-some more questions and answers. *Addiction*, 105(2), 309-310. <a href="http://dx.doi.org/10.1111/j.1360-0443.2009.02796.x">[More Information]</a>

Sanson-Fisher, R., Brand, M., Shakeshaft, A., Haber, P., Day, C., Conigrave, K., Mattick, R., Lintzeris, N., Teesson, M. (2010). Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. *Drug and Alcohol Review*, 29(5), 469-474. <a href="http://dx.doi.org/10.1111/j.1465-3362.2009.00166.x">[More Information]</a>

Forzisi, L., Mitchell, T., Bond, A., Lintzeris, N., Spofforth, N., Strang, J. (2010). Psychological Performance and Sedation Following Injectable Opioid Administration. *Heroin Addiction and Related Clinical Problems*, 12(3), 5-8.

Miller, P., McKenzie, S., Lintzeris, N., Martin, A., Strang, J. (2010). The Community Impact of RIOTT, a Medically Supervised Injectable Maintenance Clinic in South London. *Mental Health and Substance Use*, 3(3), 248-259. <a href="http://dx.doi.org/10.1080/17523281.2010.503937">[More Information]</a>

Ramasamy, P., Lintzeris, N., Sutton, Y., Taylor, H., Day, C., Haber, P. (2010). The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. *Addiction*, 105(2), 329-334. <a href="http://dx.doi.org/10.1111/j.1360-0443.2009.02765.x">[More Information]</a>

## 2009

Ridge, G., Gossop, M., Lintzeris, N., Witton, J., Strang, J. (2009). Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. *Journal of Substance Abuse Treatment*, 37(1), 95-100. <a href="http://dx.doi.org/10.1016/j.jsat.2008.09.007">[More Information]</a>

Bammer, G., Ritter, A., Kutin, J., Lintzeris, N. (2009). Fast-tracking implementation through trial design: the case of buprenorphine treatment in Victoria. *Australian and New Zealand Journal of Public Health*, 33(1), 34-39. <a href="http://dx.doi.org/10.1111/j.1753-6405.2009.00335.x">[More Information]</a>

Miller, P., Forzisi, L., Zador, D., Lintzeris, N., Metrebian, N., Waal, R., Mayet, S., Strang, J. (2009). Groin injecting in injectable opioid treatment service users in South London. *Addiction Research and Theory*, 17(4), 381-389. <a href="http://dx.doi.org/10.1080/16066350802635660">[More Information]</a>

Haber, P., Lintzeris, N., Proude, E., Lopatko, O. (2009). *Guidelines for the Treatment of Alcohol Problems*, Publications Number: P3 -5625, (pp. vii - 232). Canberra, Australia: Commonwealth Department of Health and Ageing.

Degenhardt, L., Larance, B., Bell, J., Winstock, A., Lintzeris, N., Ali, R., Scheuer, N. (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. *Medical Journal of Australia*, 191(3), 161-165. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\_uids=19645647">[More Information]</a>

Haber, P., Lintzeris, N., Morley, K. (2009). Pharmacotherapies for alcohol dependence. In Paul Haber, Elizabeth Proude, Nick Lintzeris & Olga Lopatko (Eds.), *Guidelines for the Treatment of Alcohol Problems*, (pp. 93-106). Australia: Commonwealth

of Australia.

Lintzeris, N. (2009). Prescription of heroin for the management of heroin dependence: Current status. *CNS Drugs*, 23(6), 463-476. <a href="http://dx.doi.org/10.2165/00023210-200923060-00002">[More Information]</a>

Winstock, A., Lintzeris, N., Lea, T. (2009). Why do patients report transferring between methadone and buprenorphine? *Drug and Alcohol Review*, 28(6), 686-687. <a href="http://dx.doi.org/10.1111/j.1465-3362.2009.00127.x">[More Information]</a>

## 2008

Lintzeris, N., van der Waal, R., Miller, P., Metrebian, N., Strang, J., Zador, D. (2008). The fine line between harm reduction and harm production - development of a clinical policy on femoral (groin) Injecting. *European Addiction Research*, 14(4), 213-218. <a href="http://dx.doi.org/10.1159/000141646">[More Information]</a>

Lintzeris, N., Lee, S., Scopelliti, L., Mabbutt, J., Haber, P. (2008). Unplanned admissions to two Sydney public hospitals after naltrexone implants. *Medical Journal of Australia*, 188(8), 441-444. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list\_uids=18429708">[More Information]</a>

## 2005

Digiusto, E., Lintzeris, N., Breen, C., Kimber, J., Mattick, R., Bell, J., Ali, R., Saunders, J. (2005). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. *Addictive Behaviors*, 30(3), 443-56. <a href="http://dx.doi.org/10.1016/j.addbeh.2004.06.002">[More Information]</a>